Glaxosmithkline(Gsk) Bangladesh Ltd operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Glaxosmithkline(Gsk) Bangladesh Ltd with three other
pharmaceutical manufacturers in Asia:
High Tech Pharm Company., Limited
of KOREA (SOUTH)
sales of 63.07 billion Korean Won [US$53.61 million]
of which 100%
Mekophar Chemical Pharma JSC
(1.22 trillion Vietnamese Dong [US$52.46 million]
Panion & Bf Biotech Inc.
based in TAIWAN
(1.57 billion Taiwanese Dollars [US$53.77 million]
of which 77%
During the year ended December of 2019, sales at
Glaxosmithkline(Gsk) Bangladesh Ltd were 4.47 billion Bangladeshi Taka (US$52.80 million).
decrease of 7.1%
versus 2018, when the company's sales were 4.82 billion Bangladeshi Taka.
Contributing to the drop in overall sales was the 11.1% decline
in Powder, from 4.54 billion Bangladeshi Taka to 4.04 billion Bangladeshi Taka.
However, these declines were partially offset by the increase in sales of
Oral (up 59.3% to 433.12 million Bangladeshi Taka)